提索托马布维多丁作为第二或第三线治疗复发性宫癌的治疗方法
Ignace Vergote1, Antonio González-Martín1, Keiichi Fujiwara1
1From Universitaire Ziekenhuizen Leuven, Katholieke Universiteit Leuven, and the Belgium and Luxembourg Gynaecological Oncology Group, Leuven (I.V., E.V.N.), and Centre Hospitalier Universitaire de Liège, Liege (C.G.) - all in Belgium; Cancer Center Clínica Universidad de Navarra (A.G.-M.), Hospital Universitario 12 de Octubre (L.M.), and Grupo Español de Investigación en Cáncer de Ovario (GEICO) (A.G.-M.), Madrid, and Gynecologic Cancer Program, Vall d'Hebron Institute of Oncology, Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona (A.O.) - all in Spain; Saitama Medical School International Medical Center, Saitama (K.F., K.H.), and the National Cancer Center Hospital, Tokyo (K.Y.) - both in Japan; Centre Hospitalier Universitaire de Besançon, Besançon (E.K.), and GINECO (E.K., A.A.) and Groupe Hospitalier Diaconesses Croix Saint-Simon (A.A.), Paris - all in France; Országos Onkológiai Intézet, Budapest, Hungary (A.B.); Georgia Cancer Center, Augusta University, Augusta (S.G.); Yonsei University College of Medicine (J.-Y.L.) and Samsung Medical Center, Sungkyunkwan University School of Medicine (B.-G.K.) - both in Seoul, South Korea; the Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London (S.B.), and the Christie NHS Foundation Trust, Clinical Oncology, Manchester (L.B.) - both in the United Kingdom; Hospital Beneficencia Portuguesa de São Paulo (F.C.M.), Hospital Israelita Albert Einstein de São Paulo (F.C.M.), and Instituto Brasileiro de Controle do Câncer (F.M.C.) - all in Sao Paulo; Fondazione Policlinico Gemelli IRCCS and Catholic University of Sacred Heart, Rome (D.L.); Arbeitsgemeinschaft Gynäkologische Onkologie Study Group and University Medical Center Hamburg-Eppendorf, Hamburg, Germany (L.W.); Amsterdam University Medical Centers, Amsterdam (A.W.); Sunnybrook Research Institute, Toronto (A.C.); Medica Oncólogia Clinica en Grupo Gamma, Rosario, Argentina (M.R.); Skåne University Hospital and Lund University, Lund, Sweden (M.B.); First Faculty of Medicine, Charles University, General University Hospital in Prague, Prague, Czech Republic (D.C.); Pfizer, Bothell, WA (L.N., M.S.L.T., E.W.); Genmab US, Princeton, NJ (I.S.); and Mount Sinai Medical Center, Miami Beach, FL (B.M.S.).
与化疗相比,tisotumab vedotin显著改善了宫癌复发患者的整体存活率. 这种新的治疗方法为患有晚期宫癌的患者提供了更有效的选择.
科学领域:
- 在瘤学瘤学.
- 临床试验 临床试验
- 药理学 药理学是指药理学的学科.
背景情况:
- 再发性子宫癌是一个关键的挑战,治疗选择有限,第一线治疗后.
- 在初始治疗后疾病的进展需要探索替代治疗策略.
研究的目的:
- 与化疗相比,评估tisotumab vedotin的疗效和安全性,以治疗复发性或转移性宫癌的第二或第三线治疗.
主要方法:
- 一个第三阶段,多国,开放标签试验随机选择了502名患有复发性或转移性宫癌的患者.
- 患者接受了tisotumab vedotin单疗法或研究人员选择的化疗.
- 主要终点是整体存活率.
主要成果:
- 提索托马布维多丁 (tisotumab vedotin) 显示平均整体存活时间明显长 (11.5个月与9.5个月),死亡风险降低了30%.
- 使用tisotumab vedotin (4.2个月与2.9个月相比) 的无进展生存期也得到改善.
- 与化疗 (5.2%) 相比,tisotumab vedotin (17.8%) 的客观反应率更高.
结论:
- 在接受二线或三线治疗的复发性宫癌患者中,tisotumab vedotin的疗效明显大于化疗.
- 这项由Genmab和Seagen资助的研究提供了tisotumab vedotin作为一种有价值的治疗选择的证据.
更多相关视频
07:29Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
相关概念视频
Tumor Immunotherapy
Targeted Cancer Therapies
There are several types of targeted therapies against...
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
